Skip Nav Destination
Issues
Editorial
Minireview
The Biology Behind
Advances in Brief
Clinical Trials
Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy1
Blanca Segura-Pacheco; Catalina Trejo-Becerril; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Ignacio Mariscal; Alma Chavez; Carmen Acuña; Ana Maria Salazar; Marcela Lizano; Alfonso Dueñas-Gonzalez
Molecular Oncology, Markers, Clinical Correlates
Experimental Therapeutics, Preclinical Pharmacology
Regular Articles
Clinical Trials
Phase I Study of TLK286 (Glutathione S-Transferase P1-1 Activated Glutathione Analogue) in Advanced Refractory Solid Malignancies1
Lee S. Rosen; Joseph Brown; Bernadette Laxa; Leny Boulos; Laura Reiswig; William D. Henner; Robert T. Lum; Steve R. Schow; Christopher A. Maack; James G. Keck; Julie C. Mascavage; Jacqueline A. Dombroski; Reinaldo F. Gomez; Gail L. Brown
A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer1
Andrew M. Scott; Greg Wiseman; Sydney Welt; Alex Adjei; Fook-Thean Lee; Wendie Hopkins; Chaitan R. Divgi; Lorelei H. Hanson; Paul Mitchell; Denise N. Gansen; Steven M. Larson; James N. Ingle; Eric W. Hoffman; Paul Tanswell; Gerd Ritter; Leonard S. Cohen; Peter Bette; Lisa Arvay; Andree Amelsberg; Dan Vlock; Wolfgang J. Rettig; Lloyd J. Old
Efficacy and Toxicity of the Angiogenesis Inhibitor SU5416 As a Single Agent in Patients with Advanced Renal Cell Carcinoma, Melanoma, and Soft Tissue Sarcoma1
Bart C. Kuenen; Jose Tabernero; Jose Baselga; Franco Cavalli; Elisabeth Pfanner; Pier Franco Conte; Siegfried Seeber; Srinivasan Madhusudan; Gael Deplanque; Holgen Huisman; Paul Scigalla; Klaas Hoekman; Adrian L. Harris
Phase I Evaluation of Sequential Topoisomerase Targeting with Irinotecan/Cisplatin Followed by Etoposide in Patients with Advanced Malignancy1
Edward J. Licitra; Viral Vyas; Kathy Nelson; Rita Musanti; Stephanie Beers; Cecilia Thomas; Elizabeth Poplin; Sharon Smith; Yong Lin; Larry. J. Schaaf; Joseph Aisner; Murugesan Gounder; Rajeev Rajendra; Ahamed Saleem; Deborah Toppmeyer; Eric H. Rubin
Multicenter Randomized Phase II Study of Paclitaxel (1-Hour Infusion), Fluorouracil, Hydroxyurea, and Concomitant Twice Daily Radiation with or without Erythropoietin for Advanced Head and Neck Cancer
Fred R. Rosen; Daniel J. Haraf; Merrill S. Kies; Kerstin Stenson; Louis Portugal; Marcy A. List; Bruce E. Brockstein; Bharat B. Mittal; Alfred W. Rademaker; Mary Ellyn Witt; Harold Pelzer; Ralph R. Weichselbaum; Everett E. Vokes
Induction Docetaxel and Carboplatin Followed by Weekly Docetaxel and Carboplatin with Concurrent Radiotherapy, then Surgery in Stage III Non-Small Cell Lung Cancer: A Phase I Study1
Lori J. Wirth; Joan Lucca; Patricia Ostler; Panos Fidias; Cathy Lynch; Pasi A. Jänne; Roy S. Herbst; Bruce E. Johnson; David J. Sugarbaker; Douglas J. Mathisen; Jeanne M. Lukanich; Noah C. Choi; Stuart M. Berman; Arthur T. Skarin
Molecular Oncolology, Markers, Clinical Correlates
Characterization of Human Lymphocyte Antigen Class I Antigen-processing Machinery Defects in Renal Cell Carcinoma Lesions with Special Emphasis on Transporter-associated with Antigen-processing Down-Regulation1
Barbara Seliger; Derek Atkins; Michaela Bock; Ulrike Ritz; Soldano Ferrone; Christoph Huber; Stefan Störkel
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Overexpression of CDC25A Phosphatase Is Associated with Hypergrowth Activity and Poor Prognosis of Human Hepatocellular Carcinomas1
Xundi Xu; Hirofumi Yamamoto; Masato Sakon; Masayoshi Yasui; Chew Yee Ngan; Hiroki Fukunaga; Tetsushi Morita; Minoru Ogawa; Hiroaki Nagano; Shoji Nakamori; Mitsugu Sekimoto; Nariaki Matsuura; Morito Monden
RECK Expression in Pancreatic Cancer: Its Correlation with Lower Invasiveness and Better Prognosis1
Toshihiko Masui; Ryuichiro Doi; Takatomo Koshiba; Koji Fujimoto; Shoichiro Tsuji; Sanae Nakajima; Masayuki Koizumi; Eiji Toyoda; Sidhartha Tulachan; Daisuke Ito; Kazuhiro Kami; Tomohiko Mori; Michihiko Wada; Makoto Noda; Masayuki Imamura
Experimental Therapeutics, Preclinical Pharmacology
Administration of Optimal Biological Dose and Schedule of Interferon α Combined with Gemcitabine Induces Apoptosis in Tumor-associated Endothelial Cells and Reduces Growth of Human Pancreatic Carcinoma Implanted Orthotopically in Nude Mice1
Carmen C. Solorzano; Rosa Hwang; Cheryl H. Baker; Corazon D. Bucana; Peter W. Pisters; Douglas B. Evans; Jerald J. Killion; Isaiah J. Fidler
Dual Action of NAMI-A in Inhibition of Solid Tumor Metastasis: Selective Targeting of Metastatic Cells and Binding to Collagen1
Gianni Sava; Sonia Zorzet; Claudia Turrin; Francesca Vita; MariaRosa Soranzo; Giuliano Zabucchi; Moreno Cocchietto; Alberta Bergamo; Stefano DiGiovine; Gabriella Pezzoni; Luigi Sartor; Spiridione Garbisa
Novel Kidney Cancer Immunotherapy Based on the Granulocyte- Macrophage Colony-stimulating Factor and Carbonic Anhydrase IX Fusion Gene
José M. Hernández; Matthew H. T. Bui; Ken-ryu Han; Hideki Mukouyama; Danielo G. Freitas; David Nguyen; Randy Caliliw; Peter I. Shintaku; Sun H. Paik; Cho-Lea Tso; Robert A. Figlin; Arie S. Belldegrun
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.